ifeel has raised $20M in Series B funding to enhance its AI-powered mental health solutions for enterprises and insurers, addressing the pressing need for effective mental health management in the workplace.
Target Information
ifeel is a prominent European mental health solution catering specifically to enterprises and insurance companies seeking to mitigate costs associated with mental health risks. The platform addresses the challenges faced in resource allocation and the supply of mental health services through its AI-powered diagnostic system, offering a versatile mix of self-care tools, chat support, and video therapy options. With a strong proven track record, ifeel delivers unique clinical and cost-saving insights to its partners by measuring, understanding, and preventing risks associated with mental health issues.
The company serves a diverse clientele, including leading enterprises and insurance firms such as Glovo, Insud Pharma, SCOR SE, Cabify, Travelperk, Spotahome, H&M, Wellhub, and Thoughtworks. Operating on a global scale, ifeel now offers its services in over 26 languages across more than 30 countries.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The mental health landscape in Spain, and indeed across Europe, has undergone substantial shifts, particularly with increasing awareness of mental health issues. Companies are increasingly recognizing the significant financial
Similar Deals
EQT Life Sciences, Sanofi Ventures, Roche Venture Fund → SpliceBio
2025
Edmond de Rothschild Investment Partners → MedLumics
2017
FinTLV Ventures and Korelya Capital
invested in
ifeel
in 2024
in a Series B deal
Disclosed details
Transaction Size: $20M